Fr
About
CELL EXPANSION
and Engineering
ExCellThera is a clinical stage cell expansion and engineering company delivering proprietary molecules and bioengineering solutions to expand and engineer various cell lines for use in novel curative therapies for patients with hematologic malignancies and other diseases.
 
Mission
Offer patients the
best chance of cure
and quality of life
Vision
Deliver the next
generation transplants
with maximal efficiency
and minimal
complication
Values
We are committed to
patients. We are dedicated
to innovation & excellence.
We are driven by data
and integrity.
Contact us
Fr
About
Validated
Track Record
UM171 discovered, optimized and composition of matter patents filed worldwide
Initial Phase I/II clinical trial to treat blood cancers (results published in The Lancet Haematology in 2020)
UM092 molecule
series discovered and in-licensed
FDA grants Orphan Drug Designation (ODD)
FDA grants Regenerative
Medicine Advanced
Therapy
(RMAT) designation
EMA grants Orphan Medicinal Product and Priority Medicines (PRIME)Designations
Publication in Cell Stem Cell regarding the Mechanism of Action of the UM171 molecule
Out-licence with
Astellas in the field of PSCs
Fr
About
LEADERSHIP
Team
ExCellThera’s leadership team is made up of experts in their respective fields.
Contact us

Guy Sauvageau

M.D., Ph.D, FRCP(C)

Co-Chief Executive Officer

Internationally recognized stem cell biologist, co-identified UM171 and co-founded the Center for cell therapy of Montreal and the Quebec Leukemia Cell Bank.

David Millette

CA, CPA, CFA, Lawyer

Co-Chief Executive and Chief Operating Officer

Over 20 years of experience in business management and advisory services. Broad range of financial, legal and strategic experience across several industries, including pharmaceuticals, life sciences and healthcare.

Anne Marinier

M.D., Ph.D.

Co-Founder and Chief Technology Officer, Chemistry

Over 25 years of experience in medicinal chemistry and drug discovery including industry expertise, co-identified UM171. Previously, she was Group Leader in the Drug Discovery Research group at Bristol-Myers Squibb.

David Desjardins

LL.M.

VP, Business and Corporate Development

20+ years of experience in business development and legal counseling for public and private companies. Previously, Director, regulatory affairs, innovation & consumer relations at Lassonde, and Senior legal counsel at National Bank.

Fr
About
LEADERSHIP
Team
ExCellThera’s leadership team is made up of experts in their respective fields.
Contact us

Pierre Caudrelier

M.D.

Chief of the Board, ExCellThera

ver 30 years of experience in various positions in the Pharma and Biotech sectors. He has published 21 articles and is inventor or co-inventor on 19 patents from 2 patent families.

Jean Proulx

M.Sc., MBA

VP, Medical and Scientific Affairs

5 years of experience in the pharmaceutical industry. Previously engaged in R&D, registration and commercialization of innovative treatments for cardiovascular, venous diseases and oncology at Servier.

Nathalie Bourgouin

M.Sc.

VP, Quality and Compliance

Over 30 years of experience in quality and compliance in Pharmaceuticals and Biotech. She was VP Compliance at Skillpad and Senior Director Global Clinical and Regulatory Affairs Compliance at Aptalis. Her expertise is developing compliant risk-based quality assurance processes.

Frank van Lier

Ph.D.

VP, Manufacturing

30 years of experience within the bio-pharma industry that covers product and process development, facility design, construction, start-up, commissioning and validation, implementation of quality systems and GMP-compliant manufacturing.

Fr
About
Board of
Directors
ExCellThera has an experienced and well-balanced board of directors.
Contact us

Michael May

Chairman of the Board, ExCellThera

President and CEO of the Centre for Commercialization of Regenerative Medicine (CCRM).

Nadine Beauger

Director

President and CEO of Institute for Research in Immunology and Cancer (IRICoR). Dr. Beauger was previously VP Scientific Liaison (IP, academia-industry relations) at that same organization that she joined in 2009.

Michael Hanley

Director

Corporate director with 25+ years of experience in senior management roles and corporate governance Previously EVP and CFO at Alcan Lead Director, Nuvei and BRP; Director, ShawCor and LyondellBasell

Guy Sauvageau

Co-Chief Executive Officer

Internationally recognized stem cell biologist, co-identified UM171 and co-founded the Center for cell therapy of Montreal and the Quebec Leukemia Cell Bank.

Fr
About
Board of
Directors
ExCellThera has an experienced and well-balanced board of directors.
Contact us

Richard Cherney

Director

Managing Partner at Davies Ward Phillips & Vineberg. 35+ years of experience as legal partner to Canadian public and private companies . Has served as a director of several public companies.

Anne Marinier

Co-Founder and Chief Technology Officer, Chemistry

25+ years of experience in medicinal chemistry . Co-founded and led IRIC’s Drug Discovery Unit, and identified UM171. Previously Group Leader in the Drug Discovery Research group at Bristol-Myers Squibb.

David Millette

CA, CPA, CFA, Lawyer

Co-Chief Executive and Chief Operating Officer

Over 20 years of experience in business management and advisory services. Broad range of financial, legal and strategic experience across several industries, including pharmaceuticals, life sciences and healthcare.

Fr
About
Scientific
Advisory Board
ExCellThera can leverage its experienced scientific advisory board across a spectrum of topics and real-world applications.
Contact us

Peter Zandstra

Ph.D., FRSC(E)

Co-founded three biotech companies, including ExCellThera and Notch Therapeutics

Director and Professor at UBC’s Michael Smith Laboratories Internationally recognized cell engineering expert.

Steve Woodside

Ph.D.

Senior Director, Engineering at Notch Therapeutics

Previously held senior development positions at STEMCELL Technologies. 20+ years of experience in science and technology R&D.

Andromachi (Machi) Scaradavou

M.D.

Transplant Physician at Memorial Sloan-Kettering Cancer Center

Pediatric hematologist and oncologist with extensive experience in bone marrow transplants.

Keith Humphries

M.D., Ph.D., FRCP(C)

Part of the BC Cancer Agency for 30 years. Major research interests include Gene Therapy by targeting hematopoietic stem cells with special emphasis on hemoglobinopathies.

Bernhard Gentner

M.D.

Group leader, Translational Stem Cell and Leukaemia Unit at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)

Group leader, Translational Stem Cell and Leukaemia Unit at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)